Exelderm ® (sulconazole nitrate,USP) Solution, 1.0%

Manufacturer
Sun Pharmaceutical Industries, Inc. | Contract Pharmaceulticals Limited | DPT Laboratories, Ltd.
Effective date
2020-06-25
Label type
HUMAN PRESCRIPTION DRUG LABEL
Version
7
Source
legacy-cache
Hydrated at
2026-08-01 23:24:12

Label at a glance#

ProductExelderm
Active ingredientSULCONAZOLE NITRATE
Label structure11 sections

Indications and uses

EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum , Trichophyton mentagrophytes , Epidermophyton floccosum , and Microsporum canis ; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete’s foot). Symptomatic relief usually occurs within a ...

Dosage and administration

A small amount of the solution should be gently massaged into the affected and surrounding skin areas once or twice daily. Symptomatic relief usually occurs within a few days after starting EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0%, and clinical improvement usually occurs within one week. To reduce the possibility of recurrence, tinea cruris, tinea corporis, and tinea versicolor should be treated for 3 we...

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

For topical use only. Not for ophthalmic use.

DESCRIPTION

DESCRIPTION SECTION

EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0% is a broad-spectrum antifungal agent intended for topical application. Sulconazole nitrate, USP, the active ingredient in EXELDERM SOLUTION, is an imidazole derivative with antifungal and antiyeast activity. Its chemical name is (±)-1-[2,4-Dichloro-β-[( p-chlorobenzyl)thio]phenethyl] imidazole mononitrate and it has the following chemical structure:

structure
structure

Sulconazole nitrate, USP is a white to off-white crystalline powder with a molecular weight of 460.77. It is freely soluble in pyridine; slightly soluble in ethanol, acetone, and chloroform; and very slightly soluble in water. It has a melting point of about 130°C.

EXELDERM SOLUTION contains sulconazole nitrate, USP 10 mg/mL in a solution of propylene glycol, poloxamer 407, polysorbate 20, butylated hydroxyanisole, and purified water, with sodium hydroxide and, if necessary, nitric acid added to adjust the pH.

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Sulconazole nitrate is an imidazole derivative that inhibits the growth of the common pathogenic dermatophytes including Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis. It also inhibits the organism responsible for tinea versicolor, Malassezia furfur, and certain gram positive bacteria.

A maximization test with sulconazole nitrate solution showed no evidence of irritation or contact sensitization.

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0% is a broad-spectrum antifungal agent indicated for the treatment of tinea cruris and tinea corporis caused by Trichophyton rubrum, Trichophyton mentagrophytes, Epidermophyton floccosum, and Microsporum canis; and for the treatment of tinea versicolor. Effectiveness has not been proven in tinea pedis (athlete’s foot).

Symptomatic relief usually occurs within a few days after starting EXELDERM SOLUTION and clinical improvement usually occurs within one week.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0% is contraindicated in patients who have a history of hypersensitivity to any of the ingredients.

PRECAUTIONS

PRECAUTIONS SECTION

General

GENERAL PRECAUTIONS SECTION

EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0% is for external use only. Avoid contact with the eyes. If irritation develops, the solution should be discontinued and appropriate therapy instituted.

Information for Patients

INFORMATION FOR PATIENTS SECTION

Patients should be told to use EXELDERM SOLUTION as directed by the physician, to use it externally only, and to avoid contact with the eyes.

Carcinogenesis, Mutagenesis and Impairment of Fertility

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term animal studies to determine carcinogenic potential have not been performed. In vitro studies have shown no mutagenic activity.

Pregnancy

PREGNANCY SECTION

Pregnancy

TERATOGENIC EFFECTS SECTION

Sulconazole nitrate has been shown to be embryotoxic in rats when given in doses 125 times the human dose (in mg/kg). The drug at this dose given orally to rats also resulted in prolonged gestation and dystocia. Several females died during the perinatal period, most likely due to labor complications. Sulconazole nitrate was not teratogenic in rats or rabbits at oral doses of 50 mg/kg/day.

There are no adequate and well-controlled studies in pregnant women. Sulconazole nitrate should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers

NURSING MOTHERS SECTION

It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when sulconazole nitrate is administered to a nursing woman.

Pediatric Use

PEDIATRIC USE SECTION

Safety and effectiveness in children have not been established.

Geriatric Use

GERIATRIC USE SECTION

Clinical studies of EXELDERM SOLUTION, 1.0%, did not include sufficient numbers of patients aged 65 years and over to determine whether they respond differently than younger patients. Other reported clinical experience has not identified differences in responses between elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

There were no systemic effects and only infrequent cutaneous adverse reactions in 370 patients treated with sulconazole nitrate solution in controlled clinical trials. Approximately 1% of these patients reported itching and 1% burning or stinging. These complaints did not usually interfere with treatment.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

A small amount of the solution should be gently massaged into the affected and surrounding skin areas once or twice daily.

Symptomatic relief usually occurs within a few days after starting EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0%, and clinical improvement usually occurs within one week. To reduce the possibility of recurrence, tinea cruris, tinea corporis, and tinea versicolor should be treated for 3 weeks.

If significant clinical improvement is not seen after 4 weeks of treatment, an alternate diagnosis should be considered.

HOW SUPPLIED

HOW SUPPLIED SECTION

EXELDERM (sulconazole nitrate, USP) SOLUTION, 1.0% is a clear, slightly viscous, colorless to slightly yellow liquid with a slight characteristic odor. It is supplied as follows:

30 mL        Plastic Bottle         NDC 10631-100-30

2 x 30 mL       Plastic Bottle         NDC 10631-100-04

Avoid excessive heat, above 40°C (104°F), and protect from light.

To report SUSPECTED ADVERSE REACTIONS, contact the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Manufactured by:

DPT Laboratories Inc.

San Antonio, TX 78215

Distributed by:

Sun Pharmaceutical Industries, Inc.

Cranbury, NJ 08512

Revised May 2018

Exelderm Solution 30mL Label

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Exelderm Solution 30mL Label
Exelderm Solution 30mL Label

Exelderm Solution 30mL Carton

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

Exelderm Solution 30mL Carton
Exelderm Solution 30mL Carton

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
10631-100-04ML - Milliliter10631-1009e349dd9-11f8-4179-a1e0-a91377ed78aa12013-02-13
10631-100-30ML - Milliliter10631-100a367cc12-569f-4f76-9ca8-dd4a93aa8adf12012-07-24

DailyMed Socrata Ingredients#

Ingredient, Type, UNII table
IngredientTypeUNIISPL versionUploaded
SULCONAZOLE NITRATEACTIVE INGREDIENT1T89100D5U4
SULCONAZOLEACTIVE MOIETY5D9HAA5Q5S4
BUTYLATED HYDROXYANISOLEINACTIVE INGREDIENTREK4960K2U4
POLOXAMER 407INACTIVE INGREDIENTTUF2IVW3M24
POLYSORBATE 20INACTIVE INGREDIENT7T1F30V5YH4
PROPYLENE GLYCOLINACTIVE INGREDIENT6DC9Q167V34
SODIUM HYDROXIDEINACTIVE INGREDIENT55X04QC32I4
WATERINACTIVE INGREDIENT059QF0KO0R4

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 9 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
10631-10010631-100-30, 10631-100-04

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML

Inactive ingredient matches#

Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.

Inactive ingredient links page 1 of 6 · 322 matching rows.

DailyMed ingredient, IID ingredient, UNII table
DailyMed ingredientIID ingredientUNIIDosage form / routePotencyMaximum daily exposureMatch
POLYSORBATE 20POLYSORBATE 207T1F30V5YHINJECTION, SUSPENSION, EXTENDED RELEASE / INTRAMUSCULAR60 mgExact identifier — unii candidate
28 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3LIQUID / RESPIRATORY (INHALATION)10 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUPPOSITORY / VAGINAL252 mgExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRATUMORADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / INTRAVENOUS5 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / RESPIRATORY (INHALATION)8 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
POLOXAMER 407POLOXAMER 407TUF2IVW3M2GEL / TOPICAL28 mgExact identifier — unii candidate
15 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / RESPIRATORY (INHALATION)25 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3INJECTION, SOLUTION / INTRAVENOUS4000 mgExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICAPSULE, LIQUID FILLED / ORAL1.5 mgExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3INJECTION, SOLUTION / INTRAMUSCULAR4000 mgExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION / ORAL400 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION / SUBCUTANEOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UINJECTION, SOLUTION / INTRAVENOUSNAExact identifier — unii candidate
24 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / INTRAVASCULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2UTABLET, EXTENDED RELEASE / ORAL1 mgExact identifier — unii candidate
24 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CONCENTRATE / ORAL7000 mgExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3TABLET, EXTENDED RELEASE / ORAL9 mgExact identifier — unii candidate
81 equally ranked IID candidates
POLOXAMER 407POLOXAMER 407TUF2IVW3M2SUSPENSION / ORAL10 mgExact identifier — unii candidate
15 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / ENDOTRACHEALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISUSPENSION/ DROPS / OPHTHALMICADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IEMULSION / OPHTHALMIC0.02 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
POLOXAMER 407POLOXAMER 407TUF2IVW3M2CREAM / TOPICAL13 mgExact identifier — unii candidate
15 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3INJECTION / SUBCUTANEOUS1.4 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRA-ARTERIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3FILM, SOLUBLE / BUCCAL5 mgExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVENOUS456 mgExact identifier — unii candidate
174 equally ranked IID candidates
POLOXAMER 407POLOXAMER 407TUF2IVW3M2SUSPENSION/ DROPS / OPHTHALMIC1 mgExact identifier — unii candidate
15 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3OINTMENT / DENTALNAExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION / DENTAL2 %w/wExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SUSPENSION/ DROPS / OPHTHALMIC0.75 %w/vExact identifier — unii candidate
81 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3CAPSULE / ORAL1072 mgExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IDISC / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRA-ARTICULARADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISPRAY, METERED / NASALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3SOLUTION, CONCENTRATE / ORAL2590 mgExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / INTRAMUSCULAR0.35 %w/vExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3GEL, METERED / TOPICAL1225 mgExact identifier — unii candidate
81 equally ranked IID candidates
POLYSORBATE 20POLYSORBATE 207T1F30V5YHINJECTION / INTRAVENOUS30 mgExact identifier — unii candidate
28 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / SUBCONJUNCTIVALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRAVENOUSADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IAEROSOL, METERED / RESPIRATORY (INHALATION)ADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2USOLUTION / ORAL5 mgExact identifier — unii candidate
24 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / DENTALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3GEL / RECTAL3315 mgExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISPRAY / NASALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, SUSPENSION / INTRASYNOVIALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
PROPYLENE GLYCOLPROPYLENE GLYCOL6DC9Q167V3DROPS / ORAL200 mg/1mlExact identifier — unii candidate
81 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICREAM, AUGMENTED / TOPICAL6 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ISOLUTION / ORAL9120 mgExact identifier — unii candidate
174 equally ranked IID candidates
BUTYLATED HYDROXYANISOLEBUTYLATED HYDROXYANISOLEREK4960K2USYRUP / ORAL1 mgExact identifier — unii candidate
24 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IFILM, SOLUBLE / ORAL11 mgExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION / INTRAVITREALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32ICONCENTRATE / ORAL10 mg/5mlExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IOINTMENT / TOPICALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IINJECTION, POWDER, FOR SOLUTION / INTRATHECALADJ PHExact identifier — unii candidate
174 equally ranked IID candidates
SODIUM HYDROXIDESODIUM HYDROXIDE55X04QC32IGEL, METERED / TRANSDERMAL350 mgExact identifier — unii candidate
174 equally ranked IID candidates

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 44.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N018738-001EXELDERMSULCONAZOLE NITRATE1%SOLUTION / TOPICALRLD1985-08-30

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 44 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-10-15 13:18:302026-09N018738-001EXELDERM1%SOLUTION / TOPICALRLD1985-08-30c2088c7a36db…
2026-09-14 22:38:342026-08N018738-001EXELDERM1%SOLUTION / TOPICALRLD1985-08-3084e616aacf4f…
2026-08-18 06:07:402026-07N018738-001EXELDERM1%SOLUTION / TOPICALRLD1985-08-30caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-3031067a03dcf5…
2025-08-23 18:47 UTC2025-08N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-306a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-3003ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-302680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-305bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-3079d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-301e350fbaab3a…
2024-05-31 18:47 UTC2024-05N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-308072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-305c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-305d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-304b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-3074a2ff9319b5…
2022-03-09 01:35 UTC2022-03N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-3087673890dc5c…
2021-03-12 10:30 UTC2021-03N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-305aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-308869cabd3fbd…
2020-11-12 02:37 UTC2020-11N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30c0c555d07b60…
2019-12-14 00:12 UTC2019-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-303f01610625f2…
2019-09-15 20:21 UTC2019-09N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30b00525d2431f…
2019-07-19 19:46 UTC2019-07N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-306a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-301c564ffb4f44…
2023-12-20 04:57 UTC2023-12N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-309b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-303f0d92c62455…
2023-05-13 08:27 UTC2023-05N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-30053a50430f4f…
2023-01-26 05:58 UTC2023-01N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-303bdfa0b2c4d7…
2022-11-12 20:34 UTC · 5 captures of this ZIP2022-11N018738-001EXELDERM1%SOLUTION / TOPICALRLD, RS1985-08-303a93d1ddd44b…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
4df88789-d3b0-4082-bb03-a12f9113d48bb3aea089-3961-43ea-8335-8128e9bae13b2020-06-25Adverse reactionsExact identifier
spl id: 4df88789-d3b0-4082-bb03-a12f9113d48b
spl set id: b3aea089-3961-43ea-8335-8128e9bae13b

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.